astellas-white-logo

This website is intended for Healthcare Professionals in India only.

Menu
Padcev Logo

The combination of PADCEVTM with pembrolizumab is directed against 2 different targets: Nectin-4 and PD-11

cancercell
padcev immune cells
adc
anticancer
adcnectin
mab
anticancer nonclinical
tcell

Based on clinical studies, the combination of PADCEV with PD-1 inhibitors results in enhanced antitumour activity, consistent with the complementary mechanisms of MMAE-induced cell cytotoxicity and induction of immunogenic cell death, plus the up-regulation of immune function by PD-1 inhibition1

1L – first-line; ADC – antibody-drug conjugate; IgG1 – immunoglobulin G1; mAB – monoclonal antibody; MMAE – monomethyl auristatin E; MoA – mechanism of action; PD-1 – programmed death receptor-1; PD-L1 – programmed death-ligand 1; PD-L2 – programmed death-ligand 2

References

  1. PADCEV India prescribing information.
  2. Pembrolizumab Summary of Product Characteristics.

Efficacy outcomes

Review efficacy outcomes in 1L unresectable or metastatic UC

Safety outcomes


See safety results for 1L unresectable or metastatic UC

Resources and treatment support

Access resources to help navigate treatment with confidence

PADCEV, in combination with pembrolizumab, is indicated for the first-line treatment of adult patients with unresectable or metastatic urothelial cancer who are eligible for platinum-containing chemotherapy. 

 

PADCEV as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor-1 or programmed death-ligand 1 inhibitor.

Adverse Event Reporting

Adverse Events (AE) should be reported. Kindly report an adverse event/side effect related to an Astellas product on
pv@in.astellas.com or +91-226-1557-616

Have a Medical Information Question?

Medical Enquiries:

To submit a question about Astellas products, please contact us:

medinfo.id@astellas.com